Gilead raises full-year sales outlook as HIV sales rise 18%
Gilead reported an 18% rise in quarterly HIV sales. The body begins to report quarterly adjusted EPS but provides no figure.
Related stories
Amazon and Intel post worse-than-expected results
Investors have grown wary of the AI trade as surging debt and financing costs outpace revenues and push firms into negative cash flows. Amazon and Intel reported worse-than-expecte
L impact | EARNINGS | Oct 30, 2026, 10:39 AM UTC
BP Cuts Net Debt as Third-Quarter Profit Nearly Quadruples
BP reported third-quarter underlying replacement-cost profit of $8.46 billion, nearly four times the year-earlier level, and said cash flow jumped, enabling it to cut net debt fast
H impact | EARNINGS | Oct 30, 2026, 10:38 AM UTC
Anthropic is now SpaceX’s biggest customer
The results, published in SpaceX’s last quarter results, sparked fears over the intense concentration of the tech market. Anthropic became SpaceX’s biggest customer, accounting for
L impact | EARNINGS | Oct 30, 2026, 10:37 AM UTC
Regeneron Reports Q3 EPS of $20.07, $3.65 Above Expectations
Regeneron reported Q3 earnings of $20.07 per share, excluding non-recurring items, $3.65 better than expectations. Revenue also beat, according to the headline.
M impact | EARNINGS | Oct 30, 2026, 10:34 AM UTC
Intel Forecasts December-Quarter Sales and Profit Below Analyst Expectations
Intel cited ongoing PC-market challenges, manufacturing bottlenecks and high production-expansion spending. Its shares fell significantly in overnight trading.
H impact | EARNINGS | Oct 30, 2026, 10:32 AM UTC
Exxon Mobil reports third-quarter EPS of $3.72
H impact | EARNINGS | Oct 30, 2026, 10:30 AM UTC